The diabetes drug alogliptin did not appear to increase the odds of heart attack, stroke or cardiac death compared with placebo in type 2 diabetes patients with cardiovascular problems, a study in The New England Journal of Medicine revealed. Data on 5,380 patients showed 11.3% of those in the alogliptin arm died from heart problems or suffered a heart attack or stroke, compared with 11.8% of those who took a placebo.

Full Story:

Related Summaries